Pfizer awards grants for breast cancer research programs.
+ Technology/Innovation
Jamie Barrand | Dec 8, 2015

Pfizer awards more than $4 million in grants for breast cancer research programs

The development of new therapies for breast cancer got a boost recently from Pfizer, Inc.'s first-ever Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards.

The grants, which represent more than $4 million in funding, will support five clinical research studies on Ibrance (palbociclib), a Pfizer product taken orally for the treatment of breast cancer.

The leaders of the selected programs are Dr. Sara Tolaney, of the Dana-Farber Cancer Institute; Dr. Ewa Mrozek, of The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; Dr. Oana Danciu, of University of Illinois at Chicago; Dr. Cesar Augusto Santa-Maria, of Northwestern University; and Dr. Filipa Lynce, of Lombardi Comprehensive Cancer Center at Georgetown University Medical Center.

“We are excited to support these five investigator-led studies, which we believe will contribute important new information to our body of knowledge about the role Ibrance plays in the treatment and clinical management of advanced breast cancer,” Dr. Julia Smith, senior medical director at Pfizer Oncology, said. “At the same time, we are looking forward to continuing the program in 2016 and further supporting investigators’ efforts in this disease area, where there is a substantial need for research that may lead to new options and improved care for metastatic breast cancer patients."

The ASPIRE Breast Cancer Research Awards Program is an arm of ASPIRE, Pfizer’s competitive grants program. A new round of funding will be awarded in 2016.

Organizations in this story

+ Pfizer

More News